Anti-racist, anti-sexist, anti-ageist implementation science study of long-acting injectable cabotegravir and rilpivirine in clinic and community settings: ILANA primary endpoint (M12) results

AUTHORS

C. Orkin^1,2, R. Hayes³, J. Haviland⁴, Y.L. Wong⁴, K. Ring², S. Paparini³, B. Kasadha⁵, J. Fox^6,7, R. Byrne⁸, A. Clarke⁹, E. Clarke¹⁰, T.J Barber¹¹, V. Apea^3,2, on behalf of ILANA Study Group [N. Halim, S. Ullah, J. Hand, C. Mwendera]


INSTITUTIONS

¹Queen Mary University of London, SHARE Collaborative, Blizard Institute, London, United Kingdom, ²Barts Health NHS Trust, Department of Infection and Immunity, London, United Kingdom, ³Queen Mary University of London, SHARE Collaborative, Wolfson Institute for Population Health, London, United Kingdom, ⁴Queen Mary University of London, Pragmatic Clinical Trials Unit, Wolfson Institute for Population Health, London, United Kingdom, ⁵University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, United Kingdom, ⁶Kings College London, Infectious Diseases, London, United Kingdom, ⁷Guy's and St Thomas' NHS Foundation Trust, Infection and Immunity, London, United Kingdom, ⁸Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom, ⁹University Hospitals Sussex NHS foundation Trust, Royal Sussex County Hospital, Brighton, United Kingdom, ¹⁰Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom, ¹¹Royal Free London NHS Foundation Trust, London, United Kingdom